Clinical Updates

Thirty percent of rheumatoid arthritis patients who failed to respond adequately to anti-TNF therapy achieved remission from their disease when… »   

Paris, France, Friday 13 June 2008: New data presented today at EULAR 2008, the Annual Congress of the European League… »   

A nearly 7-year study of the effect of intensive blood sugar control with rosiglitazone (Avandia, GlaxoSmithKline) on the progression… »   

An experimental treatment for rheumatoid arthritis being developed by Johnson & Johnson and Schering-Plough Corp appeared to be effective… »   

Roche Holding AG’s MabThera was more effective in treating rheumatoid arthritis (RA) patients than other drugs with a more traditional… »   

An experimental injectable type 2 diabetes drug being developed by Sanofi-Aventis SA was well tolerated and significantly improved blood sugar… »   

Sanofi-Aventis SA’s drug Acomplia can significantly improve blood sugar control in patients with type 2 diabetes who are not adequately… »   

The chief executive of Allergan Inc said Wednesday its experimental drug to promote eyelash growth could be a big seller… »   

Few nursing home patients at high risk of bone fractures are given medications to strengthen their bones, a new… »   

When they work, new melanoma treatments that enlist the help of the immune system to attack tumors can have a… »   

AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and… »   

U.S. health officials are investigating whether drugs used to treat rheumatoid arthritis and Crohn’s disease are linked to cases of… »   

A germ that usually causes pimples or skin rashes caused fatal pneumonia in at least 24 otherwise young and healthy… »   

The antibody drug omalizumab (Xolair) is cost-effective for treating allergic asthma that has not responded fully to steroid inhalers… »   

Eli Lilly and Co’s chemotherapy drug Gemzar more than doubled the overall survival for early stage pancreatic cancer patients five… »